CVS Health Launches Cordavis Subsidiary To Bring Affordable Biosimilars To Market

CVS Health launched a new subsidiary called Cordavis that will focus on working directly with manufacturers to commercialize and/or co-produce affordable biosimilar products. Its first product will be Hyrimoz, a biosimilar to Humira. Cordavis is working with Sandoz to produce Hyrimoz and launch sales in the first quarter of 2024 at more than 80% less than the list price for Humira.

A biosimilar products is an FDA approved biologic medication that is highly similar to, and has no clinically meaningful differences from, a biologic medicine already approved by the FDA. Through Cordavis, CVS Health intends to develop a . . .